# National Cancer Institute (NCI): Phase 2 study completed, 17 enrolled (Adult Ovarian Granulosa Cell Tumor)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Sponsor type | NIH |
| Study | Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors |
| NCT ID | NCT06169124 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Adult Ovarian Granulosa Cell Tumor |
| Intervention types | procedure, drug |
| Target enrollment | 17 |
| Site countries | United States |
| Posted | 2023-12-13 |
| Planned start | 2024-02-08 |
| Event | Completed |
| Event date | 2026-09-28 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06169124). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.